Drug Profile
Vutiglabridin - Glaceum
Alternative Names: HSG-4112Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Glaceum
- Class Hepatoprotectants; Obesity therapies; Phenols; Pyrans; Small molecules
- Mechanism of Action Inflammation mediator inhibitors; Metabolism stimulants; Triglyceride modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Obesity
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 12 Apr 2024 Chemical structure information added
- 28 Mar 2024 Glaceum plans a phase II trial for Parkinson's disease (Early stage disease) (PO) in July 2024 (NCT06329141)
- 04 Apr 2023 Glaceum completes a phase II trial in Obesity in South Korea (PO) (NCT05197556)